Is Pliant Therapeutics Inc (PLRX) overvalued? · $77.3M cap
Pliant Therapeutics Inc (PLRX) is a biotechnology company listed on US.
This page asks whether Pliant Therapeutics Inc (PLRX) looks expensive on cached numbers — not a short thesis.
Latest reported PLRX revenue for 2024-12-31 was $0. Net income was -$210.3M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. PLRX currently screens at market cap $77.3M.
PLRX currently screens at market cap $77.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PLRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PLRX stock page for the full model, not this heading.
Not investment advice.